Jeff Ajer, BioMarin’s executive vice president and chief commercial officer, said the announcement “represents an important milestone” for the haemophilia community, as well as for patients and physicians around the world seeking access to the therapy.
Haemophilia treatment centres in Germany are currently testing patients to determine treatment eligibility, the company said, adding that final federal price negotiations in the country are ongoing.
People living with haemophilia A lack sufficient functioning factor VIII protein to help their blood clot, putting them at risk of painful and potentially life-threatening bleeds.
